Browse Companies

Pacific Health Care Organization Inc delivers integrated healthcare services focused on reducing workers’ compensation claim costs for California employers. The company has demonstrated consistent revenue growth with a 10.7% increase in FY2025, driven by expanding adoption of its managed care networks and utilization review services. Solid operating leverage and effective capital management have yielded a 57% jump in net income, while maintaining exceptionally strong liquidity with a current ratio above 34x. PFHO's future growth will hinge on regulatory developments and continued demand for carve-out and case management solutions within California's complex workers’ compensation landscape.

In its latest 10-Q filing dated May 15, 2026, PGIM Private Credit Fund disclosed the establishment of a new credit facility alongside sustained management fee waivers aimed at preserving investor alignment. The Fund operates through a tightly governed framework involving annual Board approvals of management agreements and carefully structured co-investment relief to participate alongside affiliates. These developments underscore an evolution in operational flexibility amid a competitive private credit landscape focused on middle market direct lending in the US and select global regions.

Consumer Portfolio Services, Inc. (CPSS) has reinforced its position in the subprime auto finance sector by expanding contract purchases and managed portfolio balances while maintaining credit risk controls through proprietary underwriting and collections approaches. The company's capital structure remains supported by robust securitization activity and diversified warehouse financing facilities, enabling growth despite market fragmentation and funding challenges. CPSS’s operating performance shows revenue growth with net income stability, underpinned by focused capital allocation including moderate share repurchases. Going forward, key metrics such as contract purchase pace, delinquency trends, and refinancing initiatives will be critical to monitor given increasing regulatory scrutiny and competitive pressures.

In its latest quarterly filing, Greystone Housing Impact Investors LP secured an $80 million credit facility that enhances its acquisition capacity while maintaining stable portfolio performance and routine distributions to unit holders. Governance structures continue to focus heavily on cybersecurity risk and legal compliance, underpinning operational resilience. The partnership’s strategic emphasis on multifamily and affordable housing investments, particularly mortgage revenue bonds and governmental issuer loans, positions it within a competitive yet regulatory-intensive sector. Growth prospects are tied to acquisition activity enabled by new financing and the expanding demand for impact investments, balanced against cybersecurity risks and regulatory sensitivities.

ATN International navigated a challenging 2025 marked by stable revenues near $728 million but a net loss of $14.9 million, stemming from legal disputes and operational pressures in key regions like Guyana and Bermuda. The company’s operating income improved sharply due to better cost management. A pivotal catalyst is the recent agreement to sell the majority of its tower portfolio for up to $297 million, expected to close in mid-2026, which should free capital and streamline operations. However, ongoing regulatory disputes and geopolitical risks in its Caribbean markets remain substantial uncertainties that could temper growth and returns.

Seapeak LLC, specializing in LNG and NGL maritime transport, faced significant challenges in 2024 with substantial asset impairments on older steam turbine LNG carriers due to market oversupply and diminished charterer interest. In 2025, the company undertook fleet restructuring, vessel sales, and workforce reductions while maintaining a core focus on medium- to long-term fixed-rate charters that provide revenue visibility. Despite a sharply negative operating income in 2024, Seapeak rebounded to positive operating income and modest profitability in 2025, supported by improved equity earnings from joint ventures and effective liquidity management. Going forward, growth is tied closely to newbuild deliveries and charter contracting efforts, with downside risks stemming from geopolitical uncertainties and vessel oversupply.

Magnum Ice Cream Company N.V. (MICC) emerged as an independent entity at the end of 2025, reporting €7.91 billion in revenue and €307 million in net profit for that fiscal year. Its operations span Europe and ANZ, the Americas, and AMEA regions, with nearly half of sales concentrated in Northern Hemisphere summers due to seasonality. The company is navigating risks related to operational separation and internal control establishment, while maintaining a solid liquidity position with €441 million cash on hand and a current ratio of 1.02. Future growth depends on managing commodity volatility, successful transition to standalone systems, and market expansion across its diversified geographic footprint.

DocGo Inc. demonstrated continuing expansion of its vertically integrated mobile healthcare and ambulance services in Q1 2026 with over 1.3 million patient interactions recorded across its service model, including virtual care and onsite mobile health. However, substantial labor cost pressures—comprising roughly 70% of revenue—and limited pricing flexibility under fixed reimbursement contracts are constraining margins. The company’s broad U.S. and U.K. footprint and proprietary technology platform underpin competitive advantages, yet evolving regulations, contract concentrations, and liquidity covenant breaches emphasize operational risks. DocGo’s pathway to growth hinges on deepening insurer partnerships, expanding virtual care offerings, and cost management, while navigating workforce shortages and potential covenant renegotiations.

After a difficult 2024 marked by losses, Holley Inc. experienced a significant rebound in operating income and net earnings in 2025, driven by operational improvements and product innovation. The company’s broad portfolio of over 65 automotive aftermarket brands, combined with an omni-channel distribution approach, supports resilience in a fragmented and competitive market. However, ongoing risks remain from macroeconomic volatility, supply chain pressures, tariffs, and financial leverage constraints. Future growth hinges on successful new product launches, market share expansion within established verticals, and navigating external uncertainties.

In Q1 2026, Magnachip Semiconductor reported revenues around $46 million alongside a net loss of $4.65 million, maintaining a strong liquidity position with a current ratio above 2.0. The company unified its Power IC and Power Analog Solutions businesses in 2025 to strengthen market competitiveness and operational efficiency. However, upcoming power infrastructure upgrades at its Gumi fabrication facility pose notable risks of production interruptions and manufacturing inefficiencies. Magnachip serves diverse end markets including consumer electronics, automotive, and industrial applications with a specialized analog and mixed-signal semiconductor portfolio bolstered by its in-house manufacturing capabilities.

Silvercrest Asset Management Group Inc. recorded a slight net loss of $120,000 in fiscal 2025 following volatile profitability swings in recent years, with operating income turning negative at -$884,000. Revenue showed modest growth of approximately 1.5% year-over-year, reflecting comparatively stable client activity amid broader industry fee pressures and market uncertainty. Despite earnings headwinds, Silvercrest maintained strong cash flow generation ($18.6 million CFO) and robust liquidity ($44 million cash on hand), enabling sizeable share repurchases totaling $30.5 million alongside steady dividends of $7 million. The firm’s mid-sized status includes notable brand awareness ranking (#6 by Nasdaq eVestment among peers), which may support client retention and new mandates if performance stabilizes. However, ongoing sensitivity to market conditions and investment returns continues to pose risk to profitability and asset growth prospects.

In Q1 2026, HF Foods Group Inc. opened a cutting-edge distribution center in Powder Springs, Georgia, enhancing its logistical capabilities in the Southeastern U.S. Despite this operational expansion, the company continues to face significant headwinds including sustained net losses and goodwill impairments, reflecting ongoing profitability pressures. HF Foods leverages deep cultural ties to the Asian restaurant segment and an extensive distribution network covering 95% of the contiguous U.S., but growth is constrained by competitive pressures and capital intensity.

Siddhi Acquisition Corp (SDHI) completed its IPO in April 2025, raising approximately $277 million, which it holds primarily in short-duration U.S. Treasury Bills within a Trust Account to finance a future business combination. Operating solely as a blank check company, Siddhi has no revenues and incurs net losses driven by administrative expenses partially offset by interest income. The company must complete a business combination by January 2, 2027 (subject to possible six-month extension) or liquidate. Capital allocation focuses on preserving the Trust Account principal for the transaction, while working capital needs are financed through cash on hand and potential sponsor loans.

First Foundation Inc. has experienced notable shifts from profitability to operating losses in recent years, reflecting pressures from credit provisions and merger-related expenses. Its diversified loan portfolio—spanning multifamily residential, commercial real estate, land and construction, alongside fee-based wealth management—underpins multiple revenue streams but faces margin compression and credit risk factors. The firm’s integration of FirstSun Capital Bancorp, now federally approved, aims to expand market reach and realize scale efficiencies, though operational consolidation poses challenges. Capital discipline, marked by restrained buybacks and dividends amid negative free cash flow, shapes the current capital allocation outlook. Monitoring asset quality metrics and deposit growth will be essential milestones for assessing recovery momentum.

Douglas Elliman Inc., one of the largest U.S. luxury residential brokerages, demonstrated a significant financial turnaround in fiscal 2025 after several years of operating losses. Despite a sharp 17.1% revenue decline from 2024 to 2025, the company posted $45.5 million in operating income and $15.2 million in net income, marking a clear rebound driven by operational efficiencies amid subdued transaction volumes. Concentrated exposure to high-priced luxury markets with elevated average sale prices (~$1.86 million) provides both stability and sensitivity to macroeconomic cycles, including interest rates and inventory scarcity. The company’s adoption of proprietary technology platforms and minority stakes in PropTech ventures underpin agent productivity and client engagement within a hybrid brokerage-development marketing model. However, ongoing antitrust litigation settlements and regulatory scrutiny around commissions pose meaningful risks. Capital allocation reflects a pause in dividends since 2024 and persistent negative free cash flow, highlighting the tradeoffs between growth investments and shareholder returns. The evolution of industry practices, regulatory outcomes, and geographic expansion efforts remain key milestones to watch going forward.

Ludwig Enterprises, an early-stage genomic diagnostics company, reported in its latest quarterly filing that it is set to launch clinical trials for its Revealia™ Breast test in Q2 2026, marking a significant milestone toward commercialization. The company's differentiated approach leverages mRNA inflammatory biomarkers analyzed via non-invasive cheek swabs, combined with machine-learning algorithms, offering earlier detection of inflammation-driven diseases such as cancer. Ludwig is pursuing a B2B2C commercialization model through CLIA-certified laboratory partnerships and direct-to-patient kit offerings supported by certified genetic counselors. However, substantial liquidity constraints and the nascent nature of product validation present ongoing risks that require monitoring as the company advances trial execution and market development.

Stoke Therapeutics, a clinical-stage RNA therapeutics company focused on rare genetic diseases, is advancing its lead asset zorevunersen through a global Phase 3 trial. The company’s revenue surged over 400% year-over-year in fiscal 2025, driven by collaboration milestones and licensing income, alongside a marked improvement in operating losses and cash flow. With an expanded corporate footprint and liquidity expected to fund operations into 2028, Stoke is navigating clinical and regulatory complexities amid ongoing FDA interactions. The forthcoming EMPEROR trial data readout in mid-2027 and anticipated New Drug Application submission form the near-term operational focus.

Universal Logistics Holdings, Inc. reported robust revenue growth driven primarily by its automotive-focused segments, reflecting increased outsourcing and complex supply chain integrations. However, the company faced significant operating losses influenced by a non-cash goodwill impairment in its Intermodal segment and elevated capital expenditures that strained free cash flow. Despite these challenges, ULH sustains stable dividend payouts and continues to expand through acquisitions and network growth within a fragmented North American logistics industry.

Kaltura, Inc. reported $180.9 million in revenue for fiscal 2025, reflecting a modest 1% growth over 2024, driven primarily by broad enterprise adoption and expansion in education and technology segments. The company maintains a unified platform integrating video content management with agentic AI features such as conversational interfaces to support diverse use cases across industries. Despite ongoing operating losses and negative net income, cash flow from operations remains positive, supporting ongoing investments and share repurchases aimed at strategic capital allocation. Kaltura faces key challenges including evolving regulatory compliance, competitive pressures, and the need to diversify growth beyond its core large enterprise base using product-led and developer-led initiatives.

Ardent Health, Inc. operates a network of acute care hospitals and ambulatory sites primarily through majority-owned joint ventures, achieving consistent revenue growth driven by market expansion and operational improvements. Despite a 6% revenue increase in 2025 to $6.32 billion, net income declined sharply by over 35% due to higher expenses and restructuring costs amid ongoing legal challenges. The company maintains a strong liquidity position with $710 million cash on hand, low leverage ratios post refinancing, and moderate capital expenditures. Investors should monitor margin recovery initiatives, legal case developments, joint venture performance, and potential impacts of regulatory changes on reimbursement.

Once Upon a Farm, PBC entered the public markets via its IPO in February 2026, marking a significant milestone as a Delaware public benefit corporation. Despite this transition, detailed financial data including revenue and profitability remain undisclosed, complicating conventional assessments. Market commentary suggests optimism around the company’s growth potential, framed as a compelling 'billion-dollar growth story,' but transparent guidance and milestones are yet to be communicated. Capital allocation decisions so far include equity incentive plans and indemnification agreements congruent with its emerging growth status, while shareholder return policies like dividends or buybacks have not been announced.

Getty Images disclosed in its April 2026 8-K a maintained reserve for a significant litigation judgment from 2023, planning to use its undrawn revolving credit facility to fund the payment. This development intensifies near-term liquidity and financial risk amid ongoing investment in AI-driven product enhancements and premium content partnerships. The company’s business model centers on licensing diverse visual content via ecommerce and direct sales channels, leveraging a vast library and strong event affiliations. However, high leverage, competitive pressures, and regulatory risks present challenges to growth. Monitoring debt management, AI rollout execution, and license renewal progress will be crucial ahead.

In its May 2026 quarterly filing, Kyntra Bio reports advancing clinical trials for FG-3246 and expanding commercial activity for roxadustat in Europe and Japan via its Astellas collaboration. The company maintains strong liquidity with a current ratio above 3.6, supporting ongoing R&D investments amid significant regulatory and manufacturing complexities. Kyntra Bio’s business model leverages milestone and royalty income streams alongside a patent-protected portfolio, positioning it within a competitive biopharmaceutical landscape challenged by regulatory risks and supply chain dependencies. Upcoming trial readouts and geographic expansion efforts remain key growth catalysts while operational risks tied to third-party manufacturing and regulatory approvals warrant close monitoring.

Perspective Therapeutics is pioneering targeted alpha therapies using Lead-212, focusing on precision oncology through a theranostic approach. Its clinical programs for neuroendocrine tumors, melanoma, and solid tumors progress with growing patient cohorts and dose escalations. Financially, the company continues navigating significant operating losses typical of early-stage biotech while bolstering its cash position via a $175 million equity offering to extend runway into late 2027. Manufacturing investments and intellectual property strengthen operational scalability, though regulatory and market challenges remain key risks.

Samsara Inc. reported a significant jump in revenue to $1.62 billion in fiscal year 2026, a roughly 30% increase from the prior year, driven by expanded subscriptions to its Connected Operations Platform that integrates IoT devices and AI-driven applications. The company improved its operating income loss by over 70%, narrowing net losses substantially, reflecting operational leverage as it seeks profitable scale. Key co-founders maintain substantial ownership but have initiated measured stock sale plans to enhance share liquidity. Though macroeconomic uncertainties and execution risks remain, Samsara's enhanced cash flow generation and platform ubiquity provide a solid base for future growth.

Dell Technologies posted an exceptional 374% revenue increase for fiscal year 2026, largely driven by strategic shifts in its diversified product and service portfolio. This growth surge is occurring alongside the company’s issuance of significant senior notes with maturities extending to 2036, demanding careful leverage management through cash flow generation and capital allocation. While operating cash flow expanded robustly and free cash flow remains strong, challenges persist in the form of negative equity and execution risks amid rapid industry innovation and intense competition. Monitoring upcoming debt maturities, AI adoption trends, and operational metrics will be critical to assessing Dell’s sustainable value creation going forward.

Zomedica Corp. specializes in veterinary diagnostics and therapeutic devices targeting companion animals, leveraging patented Bulk Acoustic Wave technology and a growing product lineup including TRUFORMA and VETIGEL. Despite substantial investments in R&D and expanding its manufacturing footprint, the company has experienced widening net losses and negative operating cash flow over recent years. Its strategic mix of product innovation, acquisitions, and diversified sales channels offers upside potential; however, financial sustainability remains a core risk as Zomedica continues to navigate low gross margins and high operating expenses. Future revenue growth hinges on wider adoption of its diagnostic platforms and therapeutic devices, balanced against capital constraints and competitive dynamics in veterinary health.

FutureFuel Corp. experienced a sharp earnings decline in fiscal 2025, stemming primarily from operational disruptions in its Chemicals segment and regulatory uncertainty impacting its Biofuels segment. Despite these challenges, the company’s integrated 2,200-acre manufacturing complex and long-term customer relationships provide a defensible moat in specialty chemicals. The recent IRS approval of the Clean Fuel Production Credit (CFPC) offers potential incremental support, though timing and eligibility nuances temper near-term benefits. Capital allocation remains balanced with ongoing dividends and increased capital expenditures focused on facility modernization advancing operational resilience.

Eagle Financial Services, through its subsidiary Bank of Clarke, has leveraged its longstanding presence in Virginia and Maryland to build a regional community bank footprint centered on personalized banking and wealth management services. Net income grew significantly from FY2023 to FY2024 before declining nearly 30% in FY2025 amid credit risk concentration and competitive pressures. Future growth hinges on optimizing digital transformation, expanding wealth management offerings, and managing loan portfolio risks within regulatory constraints. Capital structure reflects increased equity and robust operating cash flow growth, while leadership transition and external competitive threats frame a cautious outlook.

Hammer Technology Holdings Corp. divested its telecommunications assets in late 2024, eliminating legacy revenues and focusing on financial technology through its HammerPay mobile payments platform. The company reported zero revenue in fiscal 2025 and recorded a significant increase in operating losses due to an intangible asset impairment. HammerPay offers compliance and scalability features tailored for emerging markets, especially Africa and diaspora payment corridors. However, ongoing negative working capital and reliance on related-party debt financing raise substantial doubt about the company's ability to continue as a going concern. Key near-term factors include the commercial launch of HammerPay, user adoption, regulatory approvals, and securing additional funding.

Xsolla SPAC 1, having completed its IPO in early 2026, reported strong liquidity and nominal net income in its most recent quarter, underscoring readiness for an acquisition. As a blank check company, Xsolla’s business model centers exclusively on consummating a strategic merger or acquisition leveraging management expertise. The firm faces typical SPAC execution risks but benefits from substantial capital reserves and a management team with relevant M&A experience. Investors should monitor forthcoming announcements relating to potential targets and shareholder approval milestones.

Bumble Inc. builds on a distinct brand ethos focused on women's empowerment and safety in online dating, supported by a growing base of 3.6 million paying users across multiple apps. Despite this user growth and expanding operating cash flows, the company has seen its profitability deteriorate sharply from modest gains in 2023 to large operating and net income losses by 2025, reflecting substantial investments and market pressures. High indebtedness nearing $588 million, coupled with restrictive credit covenants, limits financial flexibility amid competitive and regulatory challenges. Going forward, Bumble’s growth hinges on successful AI-driven product innovation, member engagement, and navigating evolving digital safety regulations, while managing capital allocation carefully through buybacks rather than dividends.

PURE Bioscience has grown revenue through its patented Silver Dihydrogen Citrate (SDC) antimicrobial technology, registered with key regulatory bodies and applied across multiple industries. Despite improving operating losses, the company continues to face significant net deficits and liquidity pressures, underscoring the necessity for additional capital. Key near-term milestones include expanding customer adoption via validation trials and securing further regulatory approvals. Operational execution and successful fundraising remain critical for sustaining growth and viability.

VitaNova Life Sciences Corp, originally operating at losses with limited scale, achieved a striking turnaround with a 487.6% increase in operating income by FY2025 despite a sharp 68.3% revenue decline. The company’s business spans consulting advisory services and anti-aging healthcare products focused on NAD+ level enhancement, marketed via a diverse multi-channel strategy including e-commerce, physical retail, and direct sales. While operational leverage and margin expansion have driven recent profitability gains, growth is tempered by scale constraints, absence of insurance coverage, and reliance on brand development rather than R&D. Monitoring international expansion progress and sustaining cash flows will be crucial for VitaNova's future trajectory.

PharmaCyte Biotech, Inc. continues development of its Cell-in-a-Box® technology targeting locally advanced pancreatic cancer (LAPC) amid an ongoing FDA clinical hold. The company reported no revenues but showed a substantial net income in FY2025 driven by non-operating gains. Operating losses narrowed significantly year-over-year, supported by cost controls and strategic investments. Cash and equivalents stood at $20.2 million as of January 31, 2026, with share repurchase programs actively employed to manage capital structure. Nasdaq has issued a compliance warning due to share price below $1, with a deadline in mid-2026 to regain compliance or face delisting risks.

NAPC Defense, Inc. has secured $38 million in contracts highlighting demand for its CornerShot USA tactical products. Despite stable revenues near $85,000, operating losses widened sharply to nearly $2.5 million in fiscal 2025, reflecting increased expenses amid limited sales growth. The company faces severe liquidity constraints with a current ratio around 0.04 and negative equity but has taken corporate actions including expanding authorized shares and creating a Voting Control Preferred stock class to maintain governance control during strategic initiatives. International expansion and school safety advocacy complement commercial prospects, yet financial stability remains a key challenge.